dc.creatorMa, Cuiqing
dc.creatorSu, Shan
dc.creatorWang, Jiachao
dc.creatorWei, Lin
dc.creatorDu, Lanying
dc.creatorJiang, Shibo
dc.date.accessioned2020-07-23T16:42:03Z
dc.date.accessioned2022-09-23T18:48:37Z
dc.date.available2020-07-23T16:42:03Z
dc.date.available2022-09-23T18:48:37Z
dc.date.created2020-07-23T16:42:03Z
dc.identifier1286-4579
dc.identifierhttps://doi.org/10.1016/j.micinf.2020.05.004
dc.identifierhttp://hdl.handle.net/20.500.12010/11042
dc.identifierhttps://doi.org/10.1016/j.micinf.2020.05.004
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3507793
dc.description.abstractThe global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics
dc.publisherScience Direct
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subject2019-nCoV
dc.subjectSARS-CoV-2
dc.subjectHCoV-19
dc.subjectSARS-CoV
dc.subjectVaccine
dc.subjectCross-protection
dc.titleFrom SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development


Este ítem pertenece a la siguiente institución